Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Bill Wexler's Dog Pound -- Ignore unavailable to you. Want to Upgrade?

To: Land Shark who wrote (1888)	7/11/1999 1:58:00 PM
From: DanZ	Read Replies (1) \| Respond to of 10293

Yields, The first clinical study for Zicam was conducted by a major California University. The study is currently being reviewed by the New England Journal of Medicine, what many consider the most prestigious medical journal in the world. The science behind Zicam was briefed at a recent medical conference in Corfu Greece and was well received by the doctors and scientists there. Dr. Michael Seidman, a well respected ENT at the Henry Ford Hospital in Detroit, recently called Zicam the best new treatment for colds. Pharmaceutical buyers at Albertsons, Eckerd Drug Stores, Rite Aid, Walmart, Kmart, Target, Walgreens, have either already bought Zicam or are planning to buy it for the coming cold season. How many more third parties have to look at Zicam before Mr. Yields is satisfied that the study is sound and that GelTech didn't cook up ICAM receptors? Something tells me that you will never believe that Zicam works, no matter what evidence is presented to you. Tell that to the 5,000,000 some-odd people that will probably buy a bottle of Zicam this year and to all the well respected researchers, doctors, and pharmaceutical buyers that I tend to trust more than a short seller in GUMM. You and Bill have very lame reasons for shorting GUMM (a three minute look at the balance sheet LMAO). The loss that you posted includes an extraordinary loss due to a severance package for the departed CEO. Here's the bottom line: I don't care what you do with your money. My only reason for posting here is to make sure that the distortion of facts presented by you and Bill over the past few days was brought to light. I also posted some opinions but they are well substantiated. I have no intention of getting into a pissing match with you or anybody else on SI. That's not my style, nor is promoting or hyping stocks. I have no intentions of posting on this thread again unless other misrepresentations of the facts surrounding GumTech are discussed. IMO, Zicam is only one product that will be a big winner for GumTech in the next few months. You might want to do a pro-forma to see what nicotine gum can do to GumTech's financial statements. Bill: GUMM is restricted per Uniform Practice Code 11830 and it would be interesting to know if anybody was actually able to short it. Do you have a target and stop price on your short GUMM position? Can we assume that you have exited if either of these prices are hit? If not, you might want to post your exit as soon as practical after you trade. Do you already have a short position in GUMM or is this just a paper trade? In closing, I'd like to say that I'm not opposed to short selling. I have sold many stocks short in the past and wouldn't even be opposed to selling GUMM short at certain times that I feel are opportune. However, a short position, like a long position, should be based on sound fundamental analysis or technical analysis. IMO, the amount of fundamental analysis proclaimed by short sellers on this thread is laughable and provides no bona fide rationale for shorting the stock. The chart clearly indicates a breakout and doesn't lend itself to a good short from a risk perspective at this time. Nothing, IMO, makes GUMM a good short right now.